

PREMIA, AmoyDx to establish Asia Cancer Clinical Genomic Network

26 June 2019 | News

Under the agreement, AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia



Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, has entered into a strategic partnership agreement with Amoy Diagnostics and PREMIA Holdings (HK) Ltd.

Under the agreement, AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292, Loxo Oncology's RET (rearranged during transfection) kinase inhibitor which leverages AmoyDx's proprietary multi-gene polymerase chain reaction (PCR) and next generation sequencing (NGS) panels to identify patients with this rare genetic alteration.

Wenn Sun, founder and president of PREMIA and Li-Mou Zheng, founder and chief executive officer of AmoyDx said, "We are extremely pleased to announce this important strategic collaboration with Loxo Oncology. The number of targeted therapies on actionable genomic alterations is increasing rapidly, with an ever-growing number of Asian patients and physicians at the forefront of participating in and leading novel cancer drug development in this arena. AmoyDx and PREMIA are uniquely positioned in China and Japan to create the fastest and most efficient patient identification and enrollment network."